企业风险投资在制药企业中的发展及趋势  

Development and trends of corporate venture capital in pharmaceutical industry

作　　者：杨树俊 庞博文 周斌 YANG Shu-jun;PANG Bo-wen;ZHOU Bin(China State Institute of Pharmaceutical Industry/China National Pharmaceutical Industry Information Center,Shanghai 201203,China;Legend Capital Management Co.,Ltd.,Bejing 100190,China;HKU Business School,Hongkong 999077,China)

机构地区：[1]中国医药工业研究总院/中国医药工业信息中心,上海201203 [2]君联资本管理股份有限公司,北京100190 [3]香港大学商学院,中国香港999077

出　　处：《中国新药杂志》2023年第14期1398-1405,共8页Chinese Journal of New Drugs

摘　　要：企业风险投资(CVC)在母公司寻求外部创新、获得投资回报方面有着巨大作用,生物医药行业本身对于知识与创新具有高要求,并且在全球均处于高速发展期的阶段,CVC在生物医药行业生态系统中的功能愈发重要。本文分析了美国制药企业与我国制药企业在CVC领域的发展与趋势,对美国知名制药企业CVC近年来的投资数据进行了总结,并以复星医药旗下的复健资本作为我国制药企业CVC发展的领头羊对我国制药企业在CVC领域的发展进行了分析。最后,本文总结了CVC在生物医药行业中的优点与缺点,并期待我国药企CVC在行业高速发展期抓住机遇,成为我国生物医药行业生态系统中的重要一环。Corporate venture capital(CVC) plays a huge role as a tool for parent companies to seek external innovation and obtain return on investment.The biopharmaceutical industry itself has high requirements for knowledge and innovation,and is in a stage of rapid development around the world.Therefore,CVC in the biopharmaceutical industry ecosystem is increasingly important.This paper analyzes the CVC development and trends of American pharmaceutical companies,and summarizes the investment data of well-known American pharmaceutical companies CVC in recent years.Fosun Health Capital,as a CVC of Fosun Pharma,is analyzed in this paper as a leading example of Chinese pharmaceutical company CVC.Finally,this paper summarizes the advantages and disadvantages of CVC in the biopharmaceutical industry and expects Chinese pharmaceutical companies to seize the opportunity during the rapid development of the industry and make CVC to become an important part of the Chinese biopharmaceutical industry ecosystem.

关 键 词：企业风险投资 制药企业 发展趋势 

分 类 号：R95[医药卫生—药学]